Casdozokitug

About Coherus Oncology

Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.

About Coherus BioSciences

Coherus BioSciences has successfully pivoted from a pure-play biosimilar company to an integrated oncology firm with a dual revenue and R&D strategy. Its commercial biosimilars (UDENYCA®, YUSIMRY™) provide a cash-generative foundation, while its innovative immuno-oncology pipeline, anchored by the approved anti-PD-1 therapy LOQTORZI® (toripalimab) and novel candidates like tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27), targets significant market opportunities in oncology. The company's strategy is to leverage its commercial infrastructure and regulatory expertise to efficiently advance combination therapies that overcome immune resistance.

Therapeutic Areas